English deutsch Impressum
Sitemap Disclaimer
Company Product Investor Relations Newsroom Careers Contact
 

WILEX is developing novel cancer therapies to provide effective
and well tolerated treatment and enhance patients' quality of life.

Latest press release
17.08.2010: WILEX AG: Mandatory takeover offer from dievini Hopp BioTech has ended

Latest Ad-hoc-Announcements release
04.08.2010: WILEX AG successfully completes rights issue

RENCAREX®
Therapeutic antibody in Phase III development

Half-yearly Financial Report 2010

Mandatory Offer

Current Company Presentation

 

 

Meet WILEX:

12.-15.9.2010
Rodman & Renshaw Healthcare Conference in New York

15.-17.11.2010
BioEurope in Munich

Conference list

 

© 2006 WILEX AG